JordanSCTyanDCzerLToyodaM. Immunomodulatory actions of intravenous IVIG: Potential applications to solid organ transplantation. Pediatr Transpl.1998;2(2):92–105.
2.
JohnRLietzKBurkeE. Intravenous immunoglobulin reduces anti HLA alloreactivity and shortens wait time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation.1999;110(19 suppl):II229–235.
3.
AlexandreGPSquiffletJPDeBryereM. Present experience in a series of 26 ABO incompatible living donor allografts. Transplant Proc.1987;19:4538–4542.
4.
MontgomeryRA. Renal transplantation across HLA and ABO barriers: Integrating paired donation into desensitization protocols. Am J Transplant.2010;10(3):449–457.
5.
JordanSCToyodaMVoAA. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation.2009;88(1):1–6.
6.
SinghNPirschJSamaniegoM. Antibody-mediated rejection: Treatment alternatives and outcomes. Transplant Rev.2009; 23(1):34–46.
7.
JordanSCReinsmoenNPengA. Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol.2010;25(10):2035–2048.
8.
McDiarmidSVJordanSCKimGS. Prevention and preemptive therapy of PTLD in pediatric liver transplant recipients. Transplantation.1998;66(12):1604–1611.
9.
McDonaldRASmithJMHoM. Incidence of PTLD in pediatric renal transplant recipients receiving Basiliximab, Calcineurin Inhibitor, sirolimus and steroids. Am J Transplant.2008;8(5):984–989.
10.
LeeTCSalvadoBRooneyC. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant.2005;5(9):2222–2228.
11.
TaiCCCurtisJLSzmuszkoviczJR. Abdominal involvement in pediatric heart and lung transplant recipients with post transplant lymphoproliferative disease increases the risk of mortality. J Pediatr Surg.2008;43(12):2174–2177.
12.
NowalkAJGreenM. Epstein Barr virus associated post transplant lymphoproliferative disorder: Strategies for prevention and cure. Liver Transplant.2010;6 (suppl 2):S54–S59.
